Commit Biologics secured a $60 million seed round to advance its complement-powered immune engagers into IND-enabling work and the clinic. The company plans first patient dosing in early 2028 and intends to progress COM002 while taking a second program through preclinical-to-IND development. The Copenhagen-based startup is building a bispecific complement engager (BiCE) pipeline across oncology and autoimmune disease, aiming to direct complement-mediated cytotoxicity toward targeted pathogenic cell types such as B cells, plasma cells, and certain T cells. Funding leadership includes Ackermans & van Haaren, with AbbVie Ventures and M Ventures joining existing backers Bioqube Ventures, Korys, and Novo Holdings. The financing also reflects continued investor appetite for immune-mechanism platforms that offer differentiated effector biology beyond conventional checkpoint or depletion strategies.
Get the Daily Brief